SH
SH0.F Shionogi & Co. Ltd
- Market cap
- EUR 14.4B
- P/E
- 11.0x
- P/B
- 1.43x
- ROE
- 13.7%
- Dividend yield
- 3.14%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is SH0.F undervalued?
Graham numberSH0.F trades 16.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shionogi & Co. Ltd fundamental analysis
No fundamental analysis for Shionogi & Co. Ltd yet.
Shionogi & Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shionogi & Co. Ltd
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and busines…
Full company profileShionogi & Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shionogi & Co. Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 339B | 345B | 364B | 333B | 297B | 335B | 427B | 435B | 438B | 500B | 701B |
| Gross Profit | 261B | 271B | 309B | 277B | 245B | 280B | 364B | 377B | 374B | 417B | 573B |
| Operating Income | 108B | 115B | 139B | 131B | 117B | 110B | 149B | 153B | 157B | 167B | 230B |
| EBITDA | - | 157B | 190B | 175B | 159B | 143B | 242B | 223B | 231B | 274B | 331B |
| Net Income | 83.9B | 109B | 133B | 122B | 112B | 114B | 185B | 162B | 170B | 205B | 239B |
| EPS | 263 | 346 | 426 | 402 | 371 | 379 | 628 | 191 | 200 | 241 | 281 |
| Balance Sheet | |||||||||||
| Total Assets | 670B | 723B | 779B | 872B | 999B | 1.15T | 1.31T | 1.42T | 1.54T | 2.58T | 2.64T |
| Total Liabilities | 144B | 118B | 106B | 107B | 134B | 157B | 190B | 164B | 173B | 891B | 894B |
| Shareholders' Equity | 523B | 601B | 668B | 765B | 846B | 976B | 1.10T | 1.24T | 1.36T | 1.69T | 1.75T |
| Cash & Short-term Investments | 108B | 140B | 194B | 209B | 276B | 254B | 309B | 358B | 375B | 711B | 376B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 112B | 130B | 146B | 132B | 109B | 102B | 178B | 154B | 195B | 214B | 284B |
| Capital Expenditure | 10.4B | 5.88B | 6.55B | 8.95B | 28.2B | 26.2B | 37.2B | 28.3B | 52.1B | 31.3B | 39.4B |
| Free Cash Flow | - | 113B | 137B | 120B | 76.1B | 70.5B | 141B | 126B | 143B | 182B | 245B |
| Ratios | |||||||||||
| ROE | 16.0% | 18.1% | 19.9% | 16.0% | 13.2% | 11.7% | 16.8% | 13.1% | 12.5% | 12.2% | 13.7% |
| ROA | 12.5% | 15.1% | 17.0% | 14.0% | 11.2% | 9.9% | 14.1% | 11.4% | 11.1% | 8.0% | 9.1% |
| Net Profit Margin | 24.8% | 31.6% | 36.5% | 36.7% | 37.6% | 34.1% | 43.3% | 37.2% | 38.9% | 41.1% | 34.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shionogi & Co. Ltd dividends
- Dividend yield
- 3.14%
- Forward dividend
- 0.52 EUR
- Payout ratio
- 27.4%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 56.2B | 66 | 27.4% |
| 2025 | JPY 48.7B | 57 | 28.6% |
| 2024 | JPY 43.9B | 52 | 27.1% |
| 2023 | JPY 36.1B | 123 | 19.5% |
| 2022 | JPY 33.1B | 110 | 29.0% |
| 2021 | JPY 32.5B | 108 | 29.1% |
| 2020 | JPY 31.1B | 102 | 25.5% |
| 2019 | JPY 27.6B | 89 | 20.8% |
| 2018 | JPY 24.2B | 77 | 22.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:1 on Sep 27, 2024.
Who owns Shionogi & Co. Ltd
- Insiders 4.41%
- Institutions 60.07%
- Public & others 35.52%
- Shares outstanding 851M
- Free float 851M
Shionogi & Co. Ltd company profile
- Company name
- Shionogi & Co. Ltd
- Ticker
- SH0.F
- ISIN
- JP3347200002
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 6,223
- Fiscal year end
- March
- Address
- Park Tower, Kita, Japan, 530-0011
- Phone
- 81 6 6202 2161
- Website
- shionogi.com
About Shionogi & Co. Ltd
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothold; and research and development of mucosal vaccines. In addition, the company provides contract support services for experimental research; contract testing of agricultural production materials; solutions for education and healthcare, system development, human resource development, and training business; marketing support services; and IT services for medical and healthcare-related issues. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Kita, Japan.
Shionogi & Co. Ltd management
10- Dr. Isao Teshirogi Ph.D.CEO, President & Representative Director · born 1959
- Dr. John Apeler Keller Ph.D.Senior Exec. Officer, SVP of R&D Supervisory Unit and Pharma. Tech. Research Div. & Director · born 1964
- Takuji FujiwaraAccounting & Finance Manager
- Mr. Takeshi Shiota Ph.D.Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div.
- Mr. Yoshimasa KyokawaVice President of Corporate Communications & Secretary Office
- Yoshihiro FuruyaVice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office
- Mr. Kazuhiro HatanakaSenior Executive Officer & Senior VP of Corporate Supervisory Unit
- Akira Kato Ph.D.Senior Executive Officer & Senior VP of Supply Supervisory Unit
- Mr. Toshinobu Iwasaki Ph.D.Senior Executive Officer & Senior VP of Healthcare Business Supervisory Unit
- Masashi Deguchi Ph.D.Corporate Officer & Senior VP of Sustainability Management Division